Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 274-581-6 | CAS number: 70356-09-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 08.12.2022-31.1.2023
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 023
- Report date:
- 2023
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- 2010
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- 1-[4-(1,1-dimethylethyl)phenyl]-3-(4-methoxyphenyl)propane-1,3-dione
- EC Number:
- 274-581-6
- EC Name:
- 1-[4-(1,1-dimethylethyl)phenyl]-3-(4-methoxyphenyl)propane-1,3-dione
- Cas Number:
- 70356-09-1
- Molecular formula:
- C20H22O3
- IUPAC Name:
- 1-(4-tert-butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione
- Test material form:
- solid: particulate/powder
- Details on test material:
- - Name of test material: BMDBM, Butyl methoxydibenzoyl methane
- Substance type: mono constituent
- Appearance: Solid white to pale yellow powder
1
- Specific details on test material used for the study:
- STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: at room temperature, protected from light
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA/Ca
- Remarks:
- CBA/CaOlaHsd mice
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Envigo RMS B.V., Inc
- Microbiological status of animals, when known:
- Age at study initiation: 1st pre-test: 17 weeks; 2nd pre-test & main study: 8 - 12 weeks
- Weight at study initiation: 1st pre-test: 25 g (1 animal); 2nd pre-test: 17.1 g (1 animal) main study: 18.6 g average (16 animals)
- Housing: per group; Makrolon Type II (pre-test) / III (main study), with wire mesh top
- Diet: 2018C Teklad Global 18% protein rodent diet(certified), ad libitum
- Water: tap water, ad libitum
- Acclimation period: At least 5 days prior to the start of dosing
- Indication of any skin lesions:
ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 2°C
- Humidity: 45-65%
- Air changes (per hr): 15
- Photoperiod: artificial light 6.00 a.m. - 6.00 p.m.
Study design: in vivo (LLNA)
- Vehicle:
- dimethylformamide
- Remarks:
- The highest test item concentration, which could be technically used was a 50% solution in DMF. Vortexing was used to formulate the test item.
- Concentration:
- 10%, 25%, 50%
- No. of animals per dose:
- 4
- Details on study design:
- PRE-SCREEN TESTS:
To determine the highest non-irritant test concentration that at the same time did not induce signs of systemic toxicity, a pre-test was performed in one animal. One mouse was treated by (epidermal) topical application to the dorsal surface of each ear with a test item concentration of 50% once daily each on three consecutive days. Prior to the first application of the test item and before sacrifice the body weight was determined. Clinical signs were recorded at least once daily. Eventual signs of local irritation were documented and a score was used to grade a possible erythema of the ear skin. Furthermore, prior to the first application of the test item (day 1), on day 3 and before sacrifice (day 6) the ear thickness was determined using a micrometer. Additionally, the ears were punched after sacrifice (day 6) at the apical area using a biopsy punch (Ø 8 mm corresponding to 0.5 cm²) and were immediately pooled and weighed using an analytical balance. The animal showed an erythema of the ear skin (Score 1), and, after each application mild and unspecific signs of discomfort such as piloerection, partially closed eyes, decreased activity, and hunched posture. An erythema of ear skin could not always be determined due to substance residuals. Since a relatively high ear thickness value was determined on day 6, which was not accompanied by a similar increase in the other irritation parameters (i.e., ear weights, erythema score), a confirmatory second pre-test was performed in one further animal using a test item concentration of 50% again. The animal showed again mild and unspecific signs of discomfort such as decreased activity, hunched posture, nervousness, and partially closed eyes as well as slightly scaly ears. This time, however, all parameters for possible local skin irritation (ear weights, ear thickness, erythema score) were well within the Guideline-recommended thresholds. A possible erythema of ear skin could not always be determined due to test substance residuals.
Thus, the test item in the main study was assayed at 10, 25, and 50%. The highest concentration tested was the highest level that could be achieved whilst avoiding systemic toxicity and excessive local skin irritation as confirmed in the pre-experiment.
- Ear Thickness: In the pre-test, the ear thickness was determined prior to the first application of the test item (day 1), on day 3, and on day 6 prior to sacrifice using a micrometer.
- Ear Weights: In the pre-test, after the lymph nodes have been excised, both ears of mice were punched at the apical area using a biopsy punch (Ø 8 mm corresponding to 0.5 cm²). For each animal both
MAIN STUDY
Each test group of mice was treated by (epidermal) topical application to the dorsal surface of each ear with test item concentrations of 10, 25, and 50% in DMF. The application volume, 25 µL/ear/day, was spread over the entire dorsal surface (Ø 8 mm) of each ear once daily for three consecutive days. A further group of mice (control animals) was treated with an equivalent volume of the relevant vehicle alone (control animals).
Five days after the first topical application (day 6) 250 µL of phosphate-buffered saline containing 20.4 µCi of 3H-methyl thymidine (equivalent to 81.4 µCi/mL 3HTdR) were injected into each test and control mouse via the tail vein.
Approximately five hours after treatment with 3HTdR all mice were euthanized by using CO2, which was, after harvesting of the lymph nodes, followed by cervical dislocation to ensure death.
The draining lymph nodes were rapidly excised and pooled for each experimental group (8 nodes per group). Single cell suspensions (in phosphate buffered saline) of pooled lymph node cells were prepared by gentle mechanical disaggregation through stainless steel gauze (200 µm mesh size). After washing two times with phosphate buffered saline (approx. 10 mL) the lymph node cells were resuspended in 5 % trichloroacetic acid (approx. 3 mL) and incubated at approximately +4 °C for at least 18 hours for precipitation of macromolecules.
The precipitates were then resuspended in 5 % trichloroacetic acid (1 mL) and transferred to scintillation vials with 10 mL of scintillation liquid and thoroughly mixed. The level of 3HTdR incorporation was then measured in a β-scintillation counter. Similarly, background 3HTdR levels were also measured in two 1 mL aliquots of 5 % trichloroacetic acid. The -scintillation counter expresses 3HTdR incorporation as the number of radioactive disintegrations per minute (DPM).
- Clinical observation: All animals were observed on a daily basis, including pre- and post-dose observations on days 1, 2 and 3. Any clinical signs of systemic toxicity, local skin irritation or signs of ill health during the study were recorded.
punches were immediately weighed per animal using an analytical balance.
- Body weights: The body weights were recorded on day 1 (prior to dosing) and prior to sacrifice (pre-test) or prior to treatment with 3HTdR (main experiment) - Positive control substance(s):
- other:
- Statistics:
- The mean values and standard deviations were calculated in the body weight tables.
Results and discussion
In vivo (LLNA)
Resultsopen allclose all
- Parameter:
- SI
- Value:
- 1
- Test group / Remarks:
- control
- Parameter:
- SI
- Value:
- 1.17
- Test group / Remarks:
- 10%
- Parameter:
- SI
- Value:
- 1.48
- Test group / Remarks:
- 25%
- Parameter:
- SI
- Value:
- 1.8
- Test group / Remarks:
- 50%
- Cellular proliferation data / Observations:
- EC3 CALCULATION
The EC3 value could not be calculated, since all S.I.´s are below the threshold value of 3.
CLINICAL OBSERVATIONS:
No signs of systemic toxicity were observed during the study period.
The animals treated with test item concentrations of 25 and 50% showed a very slight erythema of the ear skin (Score 1) on test day 3 only. Animals treated with 10% test item concentration did not show any signs of local skin irritation. An erythema of ear skin could not always be determined due to substance residuals.
BODY WEIGHTS
The body weight of the animals, recorded prior to the first application and prior to treatment with 3HTdR, was within the range commonly recorded for animals of this strain and age.
Any other information on results incl. tables
Test item concentration % | Group | Measurement DPM | Calculation | Result | ||
DPM-BGa) | number of lymph nodes | DPM per lymph nodeb) | S.I. | |||
--- | BG I | 23 | --- | --- | --- | --- |
--- | BG II | 21 | --- | --- | --- | --- |
0 | 1 | 7722 | 7700 | 8 | 962.5 | 1.00 |
10 | 2 | 9042 | 9020 | 8 | 1127.5 | 1.17 |
25 | 3 | 11387 | 11365 | 8 | 1420.6 | 1.48 |
50 | 4 | 13903 | 13881 | 8 | 1735.1 | 1.80 |
1 = Control Group
2-4 = Test Group
a) = The mean value was taken from the figures BG I and BG II
b) =Since the lymph nodes of the animals of a dose group were pooled, DPM/node was determined by dividing the measured value by the number of lymph nodes pooled
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The test item was not a skin sensitiser under the test conditions of this study.
- Executive summary:
In this study the test item formulated in dimethylformamide (DMF) was assessed for its possible skin sensitising potential. For this purpose a local lymph node assay was performed using test item concentrations of 10, 25, and 50% (w/w). The highest concentration tested was the highest concentration that could be achieved whilst avoiding systemic toxicity and excessive local skin irritation as confirmed by two pre-experiments. The animals did not show any signs of systemic toxicity during the course of the study and no cases of mortality were observed. The animals treated with a test item concentration of 25 and 50% showed a very slight erythema of the ear skin (Score 1) on test day 3 only. Animals treated with 10% test item concentration did not show any signs of local skin irritation. In this study Stimulation Indices (S.I.) of 1.2, 1.5, and 1.8 were determined with the test item at concentrations of 10, 25, and 50% in DMF, respectively. The test item was not a skin sensitiser under the test conditions of this study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.